WuXi XDC

Overview

China-based ADC and bioconjugate CDMO founded approximately five years ago with integrated four-component manufacturing at a single site, expanding into Singapore and the US to address geopolitical supply chain risk. WuXi XDC's Wushi facility is one of the only sites globally performing all four ADC component manufacturing steps — antibody, linker, payload chemistry, conjugation, and drug product — under a single quality system. WuXi XDC was formally established about five years ago with a sole mission to serve the ADC and bioconjugate industry, growing to 4,000 employees from a few hundred. (Segment 4 (15:00-20:00))